Has Chandipura changed its pattern? ICMR teams visit Gujarat as samples of all 14 deceased children test negative for virus
The teams collected samples of sandflies, domestic animals and residents from villages where suspected Chandipura deaths among children have been reported since June this year.
the ICMR teams camped in four districts of the state – Panchmahal, Rajkot, Bhavnagar and Valsad – and studied the pattern of the virus.
According to officials in Panchmahal, the ICMR team visited the district last week to gather samples of sandflies, ticks, mosquitoes and other vectors along with the that of domesticated animals and cattle, rats and human beings from the areas where four deaths have been reported.
Panchmahal Chief District Health Officer Dr Vipul Gamit told The Indian Express, 'The ICMR team has gathered samples of those in the vicinity of the family that witnessed a death in the last month. They will be studied for antibodies — IgM and IgG — to understand the spread of the virus. There is a changing pattern in the virus… the same case with Japanese encephalitis, which in the recent past, has not been detected positive in laboratory tests.'
Dr Gamit said that much like 2024, the Chandipura suspected cases —that later turned out to be negative after tests in Gujarat Biotechnology Research Centre (GBRC) — emerged sporadically from villages that were unrelated to one another.
'In one case, of a five-year-old boy from Panchmahal who died, and later tested negative, the other two children living in the same house — his cousins aged 7 and 8 — did not have any symptoms and are doing well,' Dr Gamit said, adding that the symptoms include high-grade fever, convulsions, followed by diarrhoea with 'little or no time' for medical response. 'Once the respiratory organs are involved, the children cannot be saved,' he added.
Teams of ICMR also visited Bhavnagar, Valsad and Rajkot to collect samples of the vectors and other residents in close proximity to the deceased.
Officials of the Gujarat government's medical department said that the ICMR will take the samples to its laboratory in Puducherry to check if the pattern of the virus has changed in the current season. An official said, 'The sudden increase in the number of negative cases of acute encephalitis syndrome (AES), which are not showing a positive report, has prompted the ICMR to send across a team this year to study the pattern of the virus. Specific villages in certain areas where the cases have been high have been selected by the ICMR teams for the study.'
Vadodara's SSG hospital has recorded 14 deaths out of the 24 cases, including a 1.5 year old infant from Dahod, of suspected Chandipura reported this year.
In-charge Medical Superintendent and Dean of Baroda Medical College, Dr Ranjan Aiyer, said, 'Every year, around June, in the month of monsoon, Chandipura cases occur due to vectors and sandflies, especially among people living in mud houses in rural areas… This year, we received unknown virulent cases of around 24 children, who presented similar symptoms, particularly in areas of Panchmahal-Dahod and even Madhya Pradesh. They deteriorated very rapidly despite a paediatric team treating them.. However, all samples have tested negative for Chandipura.'
What is Chandipura virus?
Chandipura virus belongs to the Rhabdoviridae family, which includes rabies. It is transmitted by sandflies and mosquitoes, including Aedes aegypti, which is also a vector for dengue. The virus resides in the salivary glands of these insects and can be transmitted to humans or domestic animals through bites.
The infection can lead to encephalitis and inflammation of the brain's active tissues. The symptoms include high-grade fever, convulsions, followed by diarrhoea with 'little or no time' for medical response, according to Panchmahal Chief District Health Officer Dr Vipul Gamit.
The Chandipura virus was discovered in 1965, in the blood of two individuals suffering from febrile sickness, in a hamlet of the same name near Nagpur, Maharashtra.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Loneliness is the new silent killer: WHO warns of a global health crisis in a hyperconnected world
We've never been more connected, yet so many of us feel deeply alone. In a world filled with social media, video calls, and instant messages, loneliness is quietly becoming a major health crisis. A new report from the World Health Organization (WHO) reveals a shocking truth: loneliness is now linked to over 871,000 deaths every year. It's not just about feeling sad or isolated; it's harming our bodies and minds. From heart problems to depression, the effects are real. As this silent epidemic grows, it's time we take loneliness seriously and start rebuilding the human connections we all need. Loneliness is becoming a global health crisis despite digital connection In an era where we are constantly plugged into digital networks, sending texts, reacting with emojis, and hopping on video calls, a silent epidemic is claiming lives at an alarming rate. A new report by the World Health Organization (WHO), From Loneliness to Social Connection: Charting the Path to Healthier Societies , reveals a disturbing global paradox: despite unprecedented connectivity, loneliness is emerging as one of the most pressing public health threats of our time. According to the report, over 871,000 people die each year due to the direct and indirect effects of loneliness. That's more than 100 people every hour, a figure that rivals the global death tolls from major diseases such as heart conditions and diabetes. Far from being a fleeting emotional state, loneliness is now recognised as a risk factor for serious health issues, both physical and mental. What loneliness really means and why it affects our health The WHO defines loneliness as the gap between the relationships people have and the ones they desire. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Gentle Japanese hair growth method for men and women's scalp Hair's Rich Learn More Undo It's not merely the state of being alone but the painful feeling of being emotionally or socially disconnected. Social isolation, the objective lack of social contact, is closely related, and both conditions can lead to devastating consequences. Mounting research links loneliness to an array of health problems, including stroke, heart disease, dementia, depression, anxiety, diabetes, and even premature death. The report underscores that strong social connections act as a 'biological buffer,' reducing inflammation, regulating stress hormones, improving mental well-being, and potentially extending life expectancy. The hidden social and economic causes behind the loneliness epidemic Despite the global reach of smartphones and social media, our digital lives often lack depth. Likes, comments, and brief messages may create an illusion of interaction, but they rarely substitute for the meaningful relationships that humans truly need. As Chido Mpemba, co-chair of the WHO Commission on Social Connection, points out, even young people immersed in digital environments often report feeling profoundly alone. But screen time isn't the sole culprit. The loneliness crisis is deeply rooted in a complex web of socioeconomic and cultural factors: Poor health and disability can restrict social participation. Economic hardship leads to stress and fewer social opportunities. Urbanisation and sprawling cities have diminished traditional community spaces. A culture of hyper-independence often prizes productivity over personal connection. Lack of accessible education and shared social infrastructure can further isolate individuals. All these factors contribute to a world where forming and maintaining deep social bonds is becoming increasingly difficult. Why the WHO wants loneliness treated as a public health priority To tackle this crisis, the WHO urges governments and institutions to recognise loneliness not as a personal failing but as a systemic health issue. The report outlines a multifaceted approach to addressing the problem, calling for Policy changes that promote community engagement and inclusive urban planning Investment in research to better understand loneliness and how to combat it New ways to measure social connection and isolation, allowing for better monitoring and targeted interventions Public campaigns that encourage acts of connection, such as initiating conversations with strangers or joining local groups Above all, the WHO stresses that social connection should be treated as a core component of public health, just as vital as access to clean water, nutrition, or vaccines. How to rebuild human connection and overcome loneliness in today's fragmented world The loneliness epidemic is not an inevitable consequence of modern life but a result of systems and priorities that undervalue human connection. While there's no quick fix, even small, intentional acts, like a shared meal, a walk with a friend, or a supportive workplace, can begin to restore a sense of belonging. If societies fail to act, loneliness will continue to erode not only individual health but also the social fabric that binds communities together. The time to treat connection as essential to well-being is now because, in the end, our lives may depend on it. Also Read: Can't sleep? New research shows ancient Indian and Chinese exercises enhance sleep quality
Hindustan Times
2 hours ago
- Hindustan Times
7000 is the new 10,000 steps, finds study
For decades, fitness trackers and health apps have urged users toward the same daily goal: 10,000 steps. But new research suggests that even taking 7,000 steps a day brought significant reductions in the risk of death and major diseases. Importantly, the research found that health benefits began accumulating well before reaching either 7,000 or 10,000 steps. (Representative file photo) A comprehensive analysis of studies published between Jan 1, 2014, and Feb 14, 2025 on Thursday in The Lancet Public Health has found that taking 7,000 steps a day almost halved the risk of death and cardiovascular disease, and significantly reduced the likelihood of developing diseases such as type-2 diabetes, dementia and depression. The study, which analysed data from 57 studies involving more than 160,000 adults across 35 research cohorts, represents the most extensive examination to date of how daily step counts affect health outcomes beyond just mortality. The researchers particularly stressed on the less daunting nature of the goal. 'Although 10,000 steps per day can still be a viable target for those who are more active, 7,000 steps per day is associated with clinically meaningful improvements in health outcomes and might be a more realistic and achievable target for some,' the researchers wrote. The 10,000-step target has long been accepted as a gold standard for daily activity, appearing on fitness devices and in public health messaging worldwide. But its origins lie not in rigorous scientific research but in a 1960s Japanese marketing campaign. The number comes from Manpo-kei, a pedometer sold in Japan in 1965 whose name translates to '10,000 steps meter.' The company chose this round number partly because the Japanese character for 10,000 resembles a walking person — a clever bit of marketing that has influenced global health recommendations for decades. Current physical activity guidelines from the World Health Organization (WHO) focus primarily on minutes of moderate-to-vigorous activity rather than step counts, recommending at least 150 minutes of moderate-intensity activity per week, but have not established official step-count targets, citing insufficient evidence. 'Despite growing interest in step-based recommendations, the evidence available during the development of the 2018 Physical Activity Guidelines for Americans and the 2020 WHO Guidelines for Physical Activity and Sedentary Behaviour was considered insufficient to support the development of step count targets,' the study's authors noted. The new research examined eight health outcomes: all-cause mortality, cardiovascular disease, cancer, type 2 diabetes, cognitive outcomes including dementia, mental health, physical function, and falls. Compared with taking 2,000 steps per day — considered the lower bound of normal activity for older adults — participants who took 7,000 daily steps had: a 47% lower risk of all-cause mortality, 25% lower risk of cardiovascular disease, 47% lower risk of cardiovascular disease mortality, 37% lower risk of cancer mortality, 14% lower risk of type 2 diabetes, 38% lower risk of dementia and 22% lower risk of depressive symptoms. The likelihood of falls dropped by 28%. Importantly, the research found that health benefits began accumulating well before reaching either 7,000 or 10,000 steps. Even modest increases showed substantial improvements: people taking 4,000 steps daily had a 36% lower risk of death compared with those taking 2,000 steps. For most health outcomes, the researchers identified 'inflection points' — thresholds where additional steps provided diminishing returns. These typically occurred between 5,000 and 7,000 steps per day. 'For all outcomes, even very low step counts were associated with a risk reduction, and the HR continued to decrease with each 1,000 increment of step increase,' the authors wrote. 'Overall, the decrease in risk was attenuated before reaching 7,000 steps per day.' While taking 10,000 steps did provide additional benefits for some outcomes compared with 7,000 steps, the improvements were relatively small. For instance, 10,000 daily steps was associated with a 10% lower risk of all-cause mortality compared with 7,000 steps. The study revealed interesting variations based on age and the type of device used to measure steps. For all-cause mortality, the relationship was non-linear for younger adults, with benefits levelling off around 5,400 steps per day. For older adults, however, the relationship was linear, meaning continued benefits with each additional step. The analysis also addressed a key question for public health guidelines: whether different devices — accelerometers versus pedometers — produced similar results. The researchers found that 'the magnitude of association was similar at equivalent step counts, with minor differences in model fit for linear versus non-linear models.' The findings could have significant implications for public health messaging and individual motivation. Dr Ding Ding, the study's lead author from the University of Sydney, and colleagues suggest that emphasising a lower, more achievable target might encourage more people to become active. 'The message that every step counts for those who are able should be emphasised as a core public health message, regardless of the specific quantitative target,' the researchers wrote. The researchers acknowledged several limitations to their analysis. Most studies measured step counts at a single time point over just a few days, which 'might not accurately capture typical stepping patterns or changes over time.' Additionally, most data came from high-income countries, limiting the generalisability of findings to global populations. The researchers also noted that people with extremely low step counts might differ from more active individuals in health status and physical function, potentially affecting the results. 'Future research targeting low-income and middle-income countries and using harmonised meta-analysis and causal inference methods would further strengthen the evidence base,' they wrote.
Indian Express
4 hours ago
- Indian Express
How new ICMR vaccine gives new hope in fight against malaria
The Indian Council of Medical Research (ICMR) has announced a promising candidate vaccine for malaria, which it will now further develop, test and manufacture for commercial purposes in partnership with private companies. Known as AdFalciVax, the vaccine mainly targets two parts of Plasmodium falciparum, a pathogen that is the most common source of malaria in humans. In India, however, the disease is caused by Plasmodium vivax against which AdFalciVax is ineffective. Malaria is a parasitic infection transmitted by mosquitoes, typically causing symptoms such as fever, chills, night sweats, nausea, vomiting, and diarrhoea. In some cases, it can lead to severe complications such as seizures, fluid in the lungs, organ damage, and death. Having claimed millions of lives, malaria has been one of the deadliest diseases in human history. Currently, the disease kills about four lakh people annually, according to World Health Organization (WHO) figures. Malaria is most endemic in Africa — Nigeria, Congo, Tanzania, Mozambique, Niger, and Burkina Faso together account for more than half the yearly deaths. The disease is also present in India, although malaria deaths have sharply reduced in the country in recent years. According to the National Vector Borne Disease Control Programme (NVBDCP), reported malaria deaths stood at 1,151in 1995, and came down to only 93 in 2020 and 83 in 2022. Note that these figures are much lower than the numbers provided annually by the WHO. The organisation's 'World Malaria Report' says there were 5,511 deaths due to the disease in India in 2022. This discrepancy is due to WHO providing estimates and NVBDCP providing only the number of confirmed deaths, which may not have been officially reported. To combat malaria, scientists have been working to develop a vaccine for decades but with limited success. Recently, two vaccines—RTS,S and R21—were approved for use, but their efficacy, at 75%, is quite low. That's why the announcement about ICMR's candidate vaccine has given new hope in the fight against the disease. AdFalciVax is a chimeric recombinant vaccine — a type of vaccine that uses different parts of the genes of a pathogen (in this case, Plasmodium) to create target proteins that trigger an immune response after being injected. AdFalciVax uses two types of target proteins to prevent the spread of infection in two different ways. n It uses the circumsporozoite protein (CSP) to prevent infection in the person who has been immunised. The CSP is produced during the sporozoite stage (when a parasite can infect a new host) and the liver stage (when a parasite enters liver cells, multiplies, and then infects red blood cells) of the parasite. Subhash Singh, project manager for development of the vaccine at the ICMR-Regional Medical Research Centre, Bhubaneswar, told The Indian Express: 'Any immune response generated against these stages protects the immunised person from getting the infection.' n The vaccine also uses the Pro6C protein, a fusion of parts of two different proteins — Pfs230 and Pfs48/45 — produced by Plasmodium falciparum. This protein prevents the spread of infection in the community. 'The Pro6C protein… stops further spread of the disease by disrupting the lifecycle of the pathogen. It disrupts the development of the parasite in the midgut of a mosquito preventing further transmission,' Singh said. Unlike AdFalciVax, RTS,S and R21 only use the CSP protein, and can prevent infection only in vaccinated persons. Unlike AdFalciVax, RTS,S and R21 vaccines also do not use full-length CSP proteins. This is why the ICMR's candidate vaccine is 'likely to produce a stronger immune response and better protect against infection,' according to Singh. Researchers have found that AdFalciVax provided more than 90% protection against infection in mice. The candidate vaccine has yet to undergo rigorous human trials, and the preliminary results have been obtained only through testing on animals. Studies have also suggested that AdFalciVax produces an immune response that may last longer than that produced by the other two vaccines. Singh said: 'One of the challenges of existing vaccines is that the immune response is short-lived. People need a fifth booster shot even after four primary doses. We do not know how this will work in humans, but preliminary indications show that three doses of the ICMR candidate vaccine produced robust protection against infection in mice for more than three months. This roughly translates to a decade in human life.' AdFalciVax also contains an adjuvant — a substance used in vaccines to boost the body's immune response against the targeted disease — called alum. Singh says the use of alum is beneficial as it does not pose a risk of causing chronic inflammation, unlike adjuvants such as AS01 and Matrix M, which are used in RTS,S and R21. Alum is also known to be reliable, and has been used in numerous vaccines used in childhood immunisation programs over the years. Another advantage is that alum in AdFalciVax can remain stable at room temperature for at least nine months, according to initial studies. This might make it possible to 'transport the vaccines without maintaining the cold chain,' Singh said. The ICMR wants to partner with a company that can further develop its candidate vaccine, carry out human clinical trials, and scale up for commercial production. Although the ICMR will share the technology of developing AdFalciVax with the chosen company, it will continue to hold the intellectual property rights. Any intellectual property rights generated during the collaboration will be held jointly by the ICMR and the company. The ICMR will also earn 2% royalty on any sales of the vaccine. Authors from both the company and the ICMR will be credited in any research papers generated, and all data will be jointly owned.
